Investigating the causes of aggressive meningiomas linked to TRAF7 mutations
Molecular Mechanisms of TRAF7 Mutant Aggressive Meningiomas
This study is looking at the genetic changes in aggressive meningiomas, the most common type of brain tumor, to find out how they grow and to test new drug treatments that might help improve care for patients with these tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10829273 on NIH RePORTER |
What this research studies
This research focuses on understanding the molecular mechanisms that lead to aggressive forms of meningiomas, which are the most common primary brain tumors. The team will analyze genetic data from meningiomas to identify mutations associated with these tumors, particularly those involving the TRAF7 gene. They will also test potential drug treatments on tumor samples and mouse models to evaluate their effectiveness in targeting these specific mutations. This approach aims to provide insights into how these tumors develop and progress, potentially leading to better treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with meningiomas, particularly those with TRAF7 mutations.
Not a fit: Patients with benign meningiomas or those without TRAF7 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive meningiomas, improving their outcomes and quality of life.
How similar studies have performed: Previous research has successfully identified genetic mutations in meningiomas, suggesting that this approach has the potential for meaningful advancements in treatment.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Gunel, Murat — Yale University
- Study coordinator: Gunel, Murat
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.